Eplerenone: Will it have a role in the treatment of acute coronary syndromes?

Current Cardiology Reports

Volumn 6, Issue 4, 2004, Pages 259-263

  Meier, David J ^b   Pitt, Bertram ^b   Rajagopalan, Sanjay ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALDOSTERONE; ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; C REACTIVE PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; MINERALOCORTICOID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PYRROLIDINE DITHIOCARBAMATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; TRANDOLAPRIL; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR INFLAMMATION; CLINICAL TRIAL; COLLAGEN METABOLISM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENDOTHELIUM INJURY; ENZYME INHIBITION; HEART INFARCTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RECEPTOR BLOCKING; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SIDE EFFECT; TREATMENT PLANNING;

EID: 5444220823     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0073-0     Document Type: Article

References (29)

1. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104: 365-372.
2. Noll G, Luscher TF: The endothelium in acute coronary syndromes. Eur Heart J 1998, 19: C30-C38.
3. Freedman JE, Ting B, Hankin B, et al.: Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998, 98: 1481-1486.
4. Somers MJ, Mavromatis K, Galis ZS, Harrison DG: Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000, 101: 1722-1728.
5. Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002, 103: 425-431.
6. Liu SL, Schmuck S, Chorazcyzewski JZ, et al.: Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation Circulation 2003, 108: 2400-2406.
7. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101: 594-597.
8. Quanschning T, Ruschitzka F, Shaw S, Luscher TF: Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001, 37: 801-805.
9. Rajagopalan S, Duquaine D, King S, et al.: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105: 2212-2216.
10. Rocha R, Chander PN, Zuckerman A, Stier CT, Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats Hypertension 1999, 33: 232-237.
11. Sun Y, Zhang J, Lu L, et al.: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002, 161: 1773-1781.
12. Virdis A, Neves MF, Amiri F, et al.: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002, 40: 504-510.
13. Keidar S, Hayek T, Kaplan M, et al.: Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003, 41: 955-963.
14. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105: 1135-1143.
15. Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31: 451-458.
16. Francis J, Weiss RM, Johnson AK, Felder RB: Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. Am J Physiol Regul Integr Comp Physiol 2003, 284: R328-R335.
17. Fiebeler A, Schmidt F, Muller DN, et al.: Mineralocorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury. Hypertension 2001, 37: 787-793.
18. Harada E, Yoshimura M, Yasue H, et al.: Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001, 104: 137-139.
19. Brown NJ, Kim KS, Chen YQ, et al.: Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 85: 336-344.
20. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in human. J Clin Endocrinol Metab 2002, 87: 448-452.
21. Brown NJ, Vaughan DE, Fogo AB: Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002, 15:230-235.
22. Schafer A, Fraccarollo D, Hildemann S, et al.: Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003, 89: 1024-1030.
23. Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67: 1355-1364.
24. Usui M, Ichiki T, Katoh M, et al.: Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland Hypertension 1998, 32: 527-533.
25. Fraccarollo D, Galuppo P, Hildemann S, et al.: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003, 42: 1666-1673.
26. Suzuki G, Morita H, Mishima T, et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106: 2967-2972.
27. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES Circulation 2000, 102: 2700-2706.
28. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
29. Ward MR, Kanellakis P, Ramsey D, et al.: Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001, 104 467-472.